Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
Seeking Alpha26d
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
the products acquired from Horizon Therapeutics contributed $3.1 billion in revenue in 9M 2024. This contribution propelled the revenues driven by Amgen’s rare disease therapeutic area ...
Amgen's SWOT analysis: stock poised for growth amid obesity drug potential
Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...
precisionmedicineonline1d
Amgen's Blincyto Approved in Europe as Consolidation Treatment for Certain Newly Diagnosed Leukemia Patients
The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.